OTCMKTS:PXSLY Pharmaxis (PXSLY) Stock Price, News & Analysis → Collapse of the Petrodollar (From Colonial Metals) (Ad) Free PXSLY Stock Alerts $0.88 0.00 (0.00%) (As of 06/8/2021) Add Compare Share Share Today's Range$0.88▼$0.8850-Day Range$0.88▼$0.8852-Week Range$0.62▼$1.47VolumeN/AAverage Volume1,000 shsMarket Capitalization$26.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pharmaxis alerts: Email Address Ad Colonial MetalsThe Hidden Anchor Investment of the Elite RevealedThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Pharmaxis Stock (OTCMKTS:PXSLY)Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.Read More PXSLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PXSLY Stock News HeadlinesOctober 5, 2021 | feeds.benzinga.comProactive news headlines including Aurumin, PolarX, Valor Resources and Hartshead ResourcesSee More Headlines Receive PXSLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:PXSLY CUSIPN/A CIK1301357 Webwww.pharmaxis.com.au Phone61-2-9454-7200FaxN/AEmployees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.82 Current Ratio3.31 Quick Ratio2.92 Sales & Book Value Annual Sales$8.75 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book22.00Miscellaneous Outstanding Shares30,150,000Free FloatN/AMarket Cap$26.53 million OptionableNot Optionable Beta1.22 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Gary Jonathan Phillips (Age 60)CEO, MD & Director Comp: $375.28kMr. David Morris McGarvey BA (Age 65)CA, CPA, CFO & Company Sec. Comp: $309.66kDr. Wolfgang G. Jarolimek Ph.D. (Age 57)B.Sc. Ph.D., Head of Drug Discovery Comp: $304.82kMs. Kristen Morgan B.Sc. (Age 49)BSc, PGDipBusAdmin, MMedSc, Alliance Management - Head of Medical & Regulatory Affairs Comp: $168.68kDr. Brett Charlton Ph.D. (Age 65)MBBS Ph.D., Medical Director Comp: $304.7kMr. Cameron David Billingsley (Age 44)Gen. Counsel Dr. Dieter HamprechtHead of Chemistry for Drug DiscoveryMore ExecutivesKey CompetitorsCellectar BiosciencesNASDAQ:CLRBVerastemNASDAQ:VSTMClearside BiomedicalNASDAQ:CLSDProPhase LabsNASDAQ:PRPHLifeVantageNASDAQ:LFVNView All Competitors PXSLY Stock Analysis - Frequently Asked Questions How have PXSLY shares performed in 2024? Pharmaxis' stock was trading at $0.88 on January 1st, 2024. Since then, PXSLY stock has increased by 0.0% and is now trading at $0.88. View the best growth stocks for 2024 here. How do I buy shares of Pharmaxis? Shares of PXSLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PXSLY) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsThe Only Energy Play You Should Be Looking AtWealthpin Pro[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport Society[Webinar] Understanding Covered CallsOICWhat’s Pelosi Buying Now?AltimetryAlex's "Next Magnificent Seven" StocksThe Oxford ClubWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.